Familial Adenomatous Polyposis (APC) Gene Mutation Analysis
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder resulting from mutations of the APC gene located on the long arm of chromosome 5 (5q21). About 20% of cases are de novo (not inherited), indicating a sporadic mutation of the APC gene. APC is a tumor suppressor gene which with other tumor suppressor gene products/proteins controls cell proliferation and differentiation. Familial adenomatous polyposis generally presents as numerous (ten to up to several thousand) polyps of varying size within the large intestine, usually beginning in the teenage years. There are multiple types of APC gene mutations. The clinical manifestations and severity depend upon the location (i.e., the specific codon involved) and type of mutation within the APC 15 exon complex (e.g., nonsense, missense, frame shift mutation, etc).
APC gene mutation is the initiating event in a sequence of mutations that eventually lead to the development of cancer. Mutation penetrance is 100% in untreated patients; all patients with FAP will develop colon cancer without colectomy. Primary treatment consists of prophylactic total colectomy.
FAP accounts for approximately 1% of all colorectal cancers. FAP has several associations including: congenital hypertrophy of the retinal pigment epithelium (CHRPE), dental abnormalities, stomach fundic gland polyps, duodenum polyps, carcinoma of the periampullary region of the duodenum, osteomas, lipomas, epidermoid cysts, cholangiocarcinoma, hepatoblastoma, medulloblastoma, the cribriform variant of papillary carcinoma of thyroid, CNS tumors and desmoid tumors. Five clinical variants of FAP have been identified and consist of:
Familial adenomatous polyposis — see above.
Attenuated familial adenomatous polyposis — characterized by fewer polyps (usually fewer than 100 which tend to be located in the ascending and proximal transverse colon) and later onset of colon cancer.
Gardner syndrome (including the Hereditary desmoid disease variant) — characterized by colonic adenomatous polyps, benign osteomas, desmoid tumors and epidermoid cysts of the skin. Note: colonic adenomas may be absent.
Turcot syndrome — characterized by colonic adenomatous polyps and CNS tumors (primarily medulloblastoma variants)
MUTYH-associated polyposis (MAP) is an autosomal recessive form of adenomatous polyposis usually associated with ten to several hundred polyps, typically presenting at middle age. Some persons may not have any polyps and still will develop colon cancer. Duodenum adenomas are present in up to 25% of patients. Persons are at low risk for late onset of cancers of the ovary, bladder and skin.
Diagnosis is by identification of a mutation within the APC gene complex. Up to about 90% of APC gene mutations can be detected by modern gene sequencing methods.
- Diagnostic testing for familial adenomatous polyposis. Predictive testing for familial adenomatous polyposis
- Confirmation of familial adenomatous polyposis diagnosis for patients presenting with clinical features
- Confirmation of a clinical diagnosis of Attenuated FAP, Gardner syndrome, Turcot syndrome, or MAP
- Predictive testing for familial adenomatous polyposis upon identification of family member with existing mutation
- Screening individuals at risk for an APC-associated polyposis or MAP due to family history but without a known familial mutation
- Detection of a single mutation in the APC gene is predictive of FAP or APC-associated polyposis and will require further testing and management.
- Detection of two MUTYH mutations, on opposite chromosomes, is predictive of MAP. MUTYH sequencing is recommended for symptomatic individuals with only one identifiable MUTYH mutation.
- An intermediate result means that although a gene mutation was detected, it is unknown whether the mutation is pathogenic or benign. Medical management should rely on clinical findings and the patient’s family history.
Negative for mutation analyzed (Negative for APC genetic mutations)
EDTA whole blood (lavender top tube), or ACD whole blood (blue top tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Orphanet J Rare Dis. 2009 Oct 12;4:22. [PMID: 19822006]
- Am J Gastroenterol. 2006 Feb;101(2):385-98. [PMID: 16454848]
- N Engl J Med. 1990 Mar 29;322(13):904-8. [PMID: 2156161]
- Nat Med. 1999 Sep;5(9):1071-5. [PMID: 10470088]
- Lancet. 2003 Jul 5;362(9377):39-41. [PMID: 12853198]